Genmab | GEN - Przychody Ze Sprzedaży





Obroty Zmiana Data
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Almirall EUR 602.71M 55.09M 2026-06
Amarin USD 49.22M 451K 2025-12
Amgen USD 10.1B 1.48B 2026-06
argenx SE USD 1.36B 240M 2026-06
AstraZeneca USD 15.38B 90M 2026-06
Bayer EUR 10.87B 2.54B 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Demant DKK 6.67B 420M 2026-06
Exelixis USD 628.69M 17.89M 2026-06
Fresenius Medical Care EUR 4.86B 250M 2026-06
Genmab DKK 1.16B 259M 2026-06
GlaxoSmithKline GBP 8.41B 781M 2026-06
GN Store Nord DKK 2.17B 1.68B 2026-06
GRIFOLS EUR 1.87B 170M 2026-06
Hikma Pharmaceutical USD 1.69B 863M 2025-12
Insmed USD 425.49M 119.53M 2026-06
Lakefront Biotherapeutics EUR 12.11M 5.61M 2026-06
Lonza CHF 3.58B 63M 2025-06
Merck EUR 5.43B 300M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sanofi EUR 11.95B 710M 2026-06
UCB EUR 4.25B 764M 2025-12